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The quest for a cure for HIV remains a timely and key challenge for the HIV research community. 
Despite significant scientific advances, current HIV therapy regimens do not completely eliminate 
the negative impact of HIV on the immune system; and the economic impact of treating all people 
infected with HIV globally, for the duration of their lifetimes, presents significant challenges. This 
article discusses, from a multi-disciplinary approach, critical social, behavioral, ethical, and 
economic issues permeating the HIV cure research agenda. As part of a search for an HIV cure, 
both the perspective of patients/participants and clinical researchers should be taken into account. 
In addition, continued efforts should be made to involve and educate the broader community.
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HIV cure research background
Significant advances in the optimization of HIV treatment and care have led to life 
expectancies of HIV-infected individuals similar to uninfected individuals [1–3]. However, 
current HIV therapy regimens can induce life-long toxicities and do not completely 
eliminate the negative impact that HIV has on systemic inflammation and the immune 
system [4, 5]. Moreover, the sheer economic impact of treating all people living with HIV 
globally for the duration of their lifetimes presents significant economic challenges. As 
such, the quest for a cure for HIV remains a timely and key challenge for the HIV research 
community.
The past five years have been marked by a growing interest and engagement in HIV cure 
research and a rapidly expanding literature on the topic. While the majority of HIV cure 
research has been in the domain of biomedical, translational, and clinical sciences, the 
prospect of an HIV cure generates implications that go well beyond these disciplines. The 
broader HIV cure research agenda must address the perceptions, beliefs and expectations of 
both patients/participants and clinical researchers, attend to issues of equity and access to 
HIV cure studies and future interventions, and engage and educate other stakeholders, the 
broader community and the general public as novel strategies progress to opportunities for 
implementation (Figure 1).
Basic and clinical science of HIV cure research
Biomedical science clearly has demonstrated that HIV infects CD4+ T cells and integrates 
into the host genome, with infected cells generally activated and killed by the immune 
system. A small number of cells do not die, but instead revert to a resting state [6]. These 
infected resting CD4+ T cells contain latent provirus, which can live indefinitely undetected 
by host immunity or antiretroviral therapy (ART). In addition, these cells can be reactivated 
to produce infectious virus and thereby represent a major obstacle to HIV eradication efforts 
[7]. Other HIV-infected cells such as tissue macrophages, astrocytes, and dendritic cells 
residing in different anatomic compartments (gut mucosa, genital tract, lymph nodes, and 
the central nervous system) also contribute to the persistent latent reservoir, rendering viral 
control or elimination quite complex [8–10]. Despite these challenges, HIV cure researchers 
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are developing tools to better understand how viral reservoirs are established and maintained 
in order to control reactivation or eliminate viral reservoirs altogether.
As biomedical research has evolved, so has the definition of HIV cure, which currently 
includes two primary concepts: eradication (also termed “sterilizing cure”), in which HIV is 
completely eliminated from the body, and remission, in which some HIV remains present 
but is controlled below detection in the blood without antiretroviral therapy [11] and without 
provoking any adverse effects in the body. Evidence that HIV remission can be achieved 
was demonstrated from clinical research with a sub-group of patients in the VISCONTI 
cohort in France, referred to as post-treatment controllers, who were treated very early 
following HIV acquisition and were subsequently able to control the virus without the need 
for continuous therapy [12]. A more recent case, presented at the 8th IAS conference on HIV 
pathogenesis, treatment and prevention, includes an adolescent who was treated soon after 
birth until age six and has remained virally suppressed in the absence of ART for the past 12 
years (http://www.iasociety.org/Web/WebContent/File/HIV_Cure_Symposium_2015/Day2/
Abstracts/OA4_4_LB.pdf). Currently, evidence for eradication has been seen in only one 
individual, Timothy Ray Brown (also known as “The Berlin Patient”), who, in the course of 
allogeneic bone marrow transplant therapy precipitated by acute myeloid leukemia, was 
transplanted with cells resistant to HIV. All evidence to date indicates that HIV has been 
eliminated from his body with no recurrence in the absence of ART [13]. In addition to these 
results, increased understanding of HIV latency and reservoirs has opened up new avenues 
for clinical studies, which now include a range of approaches, including interventions with 
one or more drugs, immune-based therapies, latency-reversing agents, early treatment of 
HIV as close to infection as possible, gene therapy, stem cell transplantation or a 
combination of these. At this early stage of HIV cure research, much uncertainty exists 
about the optimal strategies and types of interventions, as many of the ongoing or planned 
clinical studies involve the use of new therapeutic agents and novel strategies with unknown 
toxicities and side effects, as well as having the potential for suboptimal outcomes in early-
phase experiments.
The prospect of life-long ART and the difficulty in adhering to treatment makes HIV cure a 
desirable goal for the pediatric population. Babies born to infected mothers are of key 
interest with HIV cure studies because of their favorable profile for achieving restricted HIV 
reservoir. Immediate ART close to the onset of HIV infection at birth is the standard of care 
worldwide, providing an opportunity for prompt control of HIV spreading. Babies have few 
memory CD4+ T cells that are prime targets for HIV. As a result, early treated infants may 
possess a high likelihood of reaching HIV remission. However, the limited knowledge on 
the mechanisms of latency in infants and children hinders the development of cure 
interventions for this population. Further challenges are the need for virologic/immunologic 
assays with small blood volume requirement and the lack of non-invasive methods to 
investigate HIV in tissues. Importantly, the decision for children to participate in trials is 
made by proxies, and potential risks and gains must be carefully balanced [14].
As this experimental research advances toward testing new clinical strategies, critical 
research questions emerge that must be considered from an integrated multi-disciplinary 
approach that includes social and behavioral scientists, ethicists, and modeling experts in 
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concert with biomedical and clinical researchers, and that acknowledges and optimizes the 
interdependency of researchers, patients, providers, communities, and other stakeholders.
Patient perspectives
As of early 2015, there were more than 100 HIV cure-related clinical studies being 
conducted or completed worldwide (http://www.treatmentactiongroup.org/cure/trials). An 
important component of these studies is participant safety, as they include interruption of 
antiretroviral therapy and/or invasive procedures to investigate critical endpoints, such as 
decreased reservoir size or viremic control. The planning phase for future clinical studies 
provides an opportunity to better understand how study participants actually comprehend 
and consider the risks of the clinical investigation, the experimental nature of early studies, 
and cure-related terminology (e.g. cure, remission, eradication, and analytic treatment 
interruption). Behavioral and social science research strategies allow for HIV cure-related 
research to place the needs and perspectives of people living with HIV at the center of the 
progression of clinical studies and investigate participant motivations and decision-making 
processes related to preferences for or participation in different types of intervention studies 
with various potential outcomes [15, 16].
While the field is new, a series of qualitative and quantitative studies have provided early 
findings in this regard. For example, a survey conducted among over 450 people living with 
HIV in the Netherlands suggested that no longer being able to transmit HIV to sexual 
partners was a more desirable outcome than the opportunity for the participant to interrupt 
ART alone (http://www.iasociety.org/Portals/0/Files/Cure/2012_Symposium/Verdult.pdf). 
A study of 29 Chinese patients not enrolled in HIV cure studies showed that HIV cure 
research generated hope for both physical well-being and social standing [17]. A survey 
among 20 participants who took part in a 14-day study involving serial doses of the histone 
deacetylase inhibitor (HDACi) vorinostat in Australia [18] found that “stopping HIV 
transmission to others” was the highest hypothetical benefit of study participation while 
“stopping doctor visits to monitor HIV” was ranked last. A more extensive online survey 
conducted in the United States among 2,094 people living with HIV revealed a high 
willingness to participate in HIV cure studies involving treatment interruption [19].
Qualitative evidence from the Food and Drug Administration (FDA) initiative on patient-
focused drug development for HIV cure research, which resulted in the release of the Voice 
of the Patient report, demonstrated that individuals living with HIV join HIV cure studies 
for a variety reasons, including altruism and the desire for personal benefits (http://
www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm348598.htm). These 
studies and reports focus on the perspectives and preferences of participants and people 
living with HIV not on the real-time decision-making that occurs as part of participation in a 
clinical study. In this case, there is a gap in the research that describes this decision-making 
process and links it to participant behaviors (e.g. enrollment, retention and HIV disclosure). 
There is also a gap in the inclusion of the perspectives of pregnant women living with HIV 
and possible participation of their infants in HIV cure studies. There are on-going studies in 
the United States and other countries investigating willingness to participate in HIV cure-
related research, but additional studies are needed.
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There are other aspects of the lives of people living with HIV that may affect their basic 
motivation and willingness to participate in (and advocate for) cure research that may not be 
readily apparent to basic and clinical scientists. For example, one of the legacies of the HIV/
AIDS epidemic (as it is understood and discussed by social scientists), is that of the 
construction and incorporation of an HIV-positive identity, which has been stigmatized in 
some contexts and valorized in others [20]. For decades, people living with HIV have been 
encouraged to ‘come out’ as HIV-positive, embrace it as part of their identity, and use it as a 
primary advocacy tool. At the same time that stigma and discrimination makes that process 
challenging, some groups are encouraging serostatus disclosure as a way to reduce stigma 
and discrimination through advocacy. Indeed, HIV-positive identity has been effectively 
institutionalized through such documents as the Denver Principles and Greater Involvement 
of People Living with AIDS (GIPA), as well as membership societies such as the National 
Association of People Living With AIDS (NAPWA), Global Network for and by People 
Living with HIV (GNP+), International Community of Women Living with HIV/AIDS 
(ICW), and HIV Positive Women’s Network (PWN). For people living with HIV, the extent 
to which HIV cure research calls into question core identity and membership status within 
the AIDS community, serves as a potential to reduce the negative impact of HIV stigma and 
discrimination, and/or raises issues of the construction and maintenance of different HIV-
related identities is an important social science question in and of itself, but may also affect 
the trajectory of HIV cure-related clinical research.
An in-depth understanding of patient/participant motivations, preferences, beliefs, 
expectations, identities, hopes, and decision-making process will ensure effective patient 
education, position patients to understand and interpret study outcomes, and facilitate the 
design and conduct of future HIV cure clinical studies.
Patient/study participant: clinician/researcher relationships
HIV clinicians play a key role in organizing the clinical care of patients, in addition to 
serving as principal investigators on major clinical research studies. It is important to 
understand how this dual role and relationship may influence various aspects of HIV cure 
research. This includes clinician and researcher attitudes about who should participate in 
what kind of research. Currently, most HIV cure studies represent proof-of-concept 
activities with little-to-no potential clinical benefit and high risks for the study participant 
[21, 22]. From the perspective of the clinical researcher, individuals who are identified early 
in their infection and are virally suppressed with current therapies may be the best 
candidates for early proof-of-concept studies, while women living with HIV who are also of 
childbearing potential may be excluded because of perceived safety concerns. An additional 
consideration is whether participation in one study precludes participation in subsequent 
studies and, if so, how patients and clinical researchers decide on participation or non-
participation. Other aspects of the clinician/researcher and patient/participant relationship 
include the informed consent process, the potential for therapeutic – or curative – 
misconception (i.e., when a participant does not fully understand the boundaries between 
standard clinical care and experimental clinical research) [23–25], and the management of 
the expectations of both parties.
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These concerns and considerations argue for integrating patient-centered and shared 
decision-making approaches into HIV cure research, to ensure a meaningful exchange of 
knowledge between patients/participants and clinicians/researchers in an act of collaborative 
knowledge building [26]. To date, the majority of survey research has focused on the 
patient/participant, highlighting a need for additional inquiry into the perspectives of 
clinicians and clinical researchers.
Community, policy-maker, and funder perspectives
Given the historical significance and global impact of the HIV epidemic, stakeholders in 
HIV cure-related research go beyond individual patients/participants and providers/
researchers, to include communities, policy-makers, and funders [27]. There are a host of 
relevant research questions related to these broader stakeholders, including how individuals 
and communities understand the notion of cure itself, as well as the science behind it, and 
how this affects responses to and support for various HIV cure research approaches.
A public understanding of science (PUS) approach is helpful in this regard, by unpacking 
how the general public understands and uses different knowledge in their lives—how people 
create meaning from scientific findings and incorporate it into their everyday lives and 
decision-making, and to what effect [28]. The PUS approach includes, but is not limited to, 
community engagement in research. It goes beyond a focus on recruitment and retention in 
clinical studies, or on health or HIV literacy. Rather, it investigates how the general public 
comprehends and understands what science is and does, including the way it is conducted 
and the interpretation of its results. It also includes analysis of who is conducting and 
supporting the research, and the reality of their stated or perceived interests.
With respect to HIV cure research specifically, it is important to consider how individuals 
and communities understand basic terminology (e.g., cure, remission, and eradication) [29] 
and how they weigh and balance competing notions of cure coming from different ‘experts’, 
including previous or alternative notions of HIV cure that have been discounted by scientists 
[30]. Additionally, it is important to know how the social construction of cure, including 
how cure is communicated affects what is and is not studied, as well as what is or is not 
taken up. The social construction and how it is communicated have a link to policy and 
advocacy around HIV cure research.
Policy-makers and funders are key stakeholders in HIV cure-related research. As they make 
difficult resource allocation decisions in an environment of increasingly constrained 
resources, they must weigh investing in cure research and its eventual implementation – 
something that is emergent and still aspirational – against investing in other approaches to 
ending the AIDS pandemic such as HIV vaccine research or enhancing implementation of 
methods that already exist for preventing HIV infections, such as condom use, pre-exposure 
prophylaxis (PrEP), harm reduction programs for drug users, and ART use among people 
living with HIV. Particularly in the early phases of cure research, where uncertainty 
prevails, these kinds of decisions—which are relevant to both resource-rich and resource-
poor countries and settings—are best informed by input from ethics analyses focused on 
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issues of safety and equity, and by social and economic research employing such methods as 
scenario-building, cost-effectiveness analysis, and mathematical modeling.
Cost-effectiveness analysis of current therapeutic or preventive interventions is an important 
tool for decision-making, recognizing its complexities and limitations. One example of a 
recent model by Sax and colleagues found that depending on efficacy, relapse rate and cost 
some HIV cure interventions were superior in terms of cost-savings [31]. These types of 
modeling studies may prove useful in guiding the desired performance characteristics of 
cure strategies. This approach requires selecting adequate measures of effects, which depend 
on the nature of the intervention being considered, and monetizing health effects, which can 
be sometimes difficult and/or inappropriate. For HIV cure strategies and interventions still in 
development, it is important to underline the limitations of cost-effectiveness analysis due to 
the uncertainty in HIV cure research and the potential impact of new interventions. For this 
reason, other strategies such as mathematical models that include accounting for uncertainty 
will need to be explored, for example, Value of Information analysis (VOI) which refers to 
the amount a decision-maker would be willing to pay for information prior to making a 
decision [32, 33]. These kinds of analytic strategies are detailed by Freedberg and colleagues 
in reference to HIV cure research, yet economics related research in HIV cure in general has 
yet to be fully undertaken [34].
Once an effective cure strategy is identified, implementation science will be key to 
identifying how best to operationalize it in the context of various health care systems. 
Recent experience with the development of a cure for hepatitis C virus (HCV) illustrates the 
importance of integrating these perspectives early on to anticipate and, hopefully, mitigate 
the possibility of a high-cost intervention exacerbating inequalities in access and resultant 
health disparities across populations. Even though HIV cure strategies may not be readily 
accessible and scalable right now, planning for this development is critical to the degree 
possible. For example, developing countries could improve their systems of early HIV 
diagnosis and access to ART which would benefit patients, the health care system and 
potentially further HIV cure research in these areas of the world. In addition to the health 
and prevention benefits, keeping patients virally suppressed limits the reservoir size which 
could place the individuals at an advantage to respond to future cure interventions.
Concluding remarks
HIV cure-related research (like most public health science) is not something that occurs in a 
laboratory vacuum, but rather is affected by the cultures and contexts surrounding it, and the 
inputs and actions of various stakeholders. Patients, study participants, providers, 
researchers, communities, policy-makers, and funders are key stakeholders in the pursuit of 
an HIV cure, and it is imperative to study the nature of their involvement, perspectives, and 
decision-making as these influence all phases of HIV cure research, as well as their impact 
on proposed outcomes. Social, behavioral, and economic research is necessary to ensure that 
the new HIV cure strategies and products, when available, will be scalable and accessible to 
all populations (see Outstanding Questions). The creation of academic networks, such as the 
NIH-funded HIV/AIDS Clinical Trials Networks, to bring together representatives of all 
relevant disciplines – including basic sciences, translational research, clinical research, 
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ethics, social medicine, anthropology, economics, health policy – has fostered fertile ground 
for cross-dialogue and interaction, and these networks should be further encouraged and 
strengthened. Equally important is ongoing dialogue between the public and private sectors, 
which to date, has been instrumental in promoting and accelerating HIV cure research. To 
ensure that any HIV cure strategy will be available, scalable and accessible once proven 
effective, it will be crucial to understand how governments and other payers incorporate and 
disseminate new interventions and technologies into their decision-making and how this 
affects access. It will be also crucial to understand the role and potential of media globally 
and locally to influence public engagement in HIV cure research and the implementation of 
its findings. As science advances toward a cure for HIV, it is imperative to integrate multiple 
disciplines in novel, compelling, and productive ways to ensure its ethical and effective 
application and its promise for contributing to the transformation of the HIV/AIDS 
pandemic.
Outstanding Questions
• What is the role of social science (e.g. social and behavioral research) in early 
basic research? What are the preferences, beliefs and hopes of patients, research 
participants and clinical researchers for specific HIV cure studies? What, if any, 
is the influence of social and contextual factors on biomarkers used in HIV cure 
studies? What influences patients’ willingness to participate in different HIV 
cure studies? These questions could be studied using mixed methods research as 
well as inclusion of social and behavioral surveys.
• What are the social and ethical considerations in early clinical research? What is 
the relationship of informed consent procedures and therapeutic and curative 
misconception? What is the shared-decision making process for different HIV 
cure studies? This could be studied using empirical research on informed 
consent and examing social science of decision-making frameworks.
• What are the critical aspects of community and stakeholder engagement? What 
is the perception of the community and their understanding of the scientific 
process related to HIV cure? These questions could be studied by looking at 
public understanding of science (PUS) and empirical research on community 
engagement.
• What is needed to ensure the strategies be scalable and effective in the real 
world? What is the early understanding of the potential cost-effectiveness of an 
HIV cure? What is needed regarding readiness for potential implementation, 
particularly regarding health systems and policy research? Further work could 
be done with modeling, health services research frameworks for preparedness, 
and through policy research.
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• HIV cure research remains a timely challenge due to the inability of treatment to 
eliminate the negative impact of HIV on the immune system and the economic 
impact of lifetime treatment.
• Two definitions of an HIV cure are emerging: complete elimination 
(eradication) of HIV from the body and viral control (remission) below plasma 
detection without antiretroviral therapy.
• The planning phase for clinical studies presents an opportunity to understand the 
perspectives and preferences of study participants, clinical researchers, 
stakeholders, and the general community.
• More research is needed, but early findings of some social science studies on the 
perspectives of people living with HIV of cure research suggest a desire to 
eliminate HIV transmission, willingness to participate in a range of trial designs 
for altruistic reasons and hope for personal benefit.
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Critical questions to address in the integration of social science in the HIV cure research 
agenda.
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